Myriad Genetics Europe News and Activities

Myriad Genetics Europe is owned by Myriad Genetics.

Myriad Genetics is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Myriad Genetics is a company listed under the stock ticker MYGN (US).

Myriad Genetics has a direct presence in 2 countries.

They are in:

• Pharmaceuticals33%
• Biotechnology33%
• Other33%

View the org chart displaying its 2 main executives

Most searched biographies at Myriad Genetics Europe

• Patrick Korman, Senior Director, France, Belux and Maghreb
• Apostolos Siscoglou, General Manager, Genetics

Popular executive movements at Myriad Genetics

• Raj Jampa has joined the company as Chief Technology Officer  (posted on June 2 2026).
• Kevin Haas, Chief Technology Officer, will leave the company on Mar. 24, 2026  (posted on March 17 2026).

Create your alert
to follow the executive moves at Myriad Genetics Europe.

Myriad Genetics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Myriad Genetics Europe

• New publication: Real-world study prospectively shows prognostic and predictive accuracy | Myriad International
• NICE in UK recommends EndoPredict® for tailored treatment of lymph node positive early breast cancer | Myriad International
• News Center | Page 7 of 7 | Myriad International
• Phase III validation of EndoPredict confirms prognostic power | Myriad International
• MyChoice CDx test implementation insights: From study to practice | Myriad International
• Optimizing HRD testing in ovarian cancer: Recommendations to achieve up to 98% conclusive test results | Myriad International
• The ESMO-ESGO-ESP consensus is advocating for the use of genomic instability tests validated in phase III trials | Myriad International
• Updated ESMO Guidelines 2024 | Myriad International
• MyChoice CDx® Plus HRD test validated for local pathology labs in real-world study | Myriad International
• EndoPredict at SABCS – Prospective long-term and real-world data | Myriad International
• View more press releases Close

Social media about Myriad Genetics Europe

• Myriad Genetics Europe on Wikipedia, Google News & Yahoo Finance
• Myriad Genetics Europe on LinkedIn, X (Twitter) & YouTube